Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA decisions to watch from October 3-5 include the approval of a rival to a fast-selling Pfizer heart drug, a lung cancer medicine, and an addition to Vertex's cystic fibrosis business. Prime is narrowing its gene editing research and partnering with Bristol Myers, while Lilly plans to invest $4.5 billion in advanced drug manufacturing. IGM has laid off staff ...